SUBA-Itraconazole: Phase IIb started
HedgePath began the open-label, U.S. Phase IIb SCORING trial to evaluate 100 mg oral SUBA-Itraconazole twice
Gathering data...
HedgePath began the open-label, U.S. Phase IIb SCORING trial to evaluate 100 mg oral SUBA-Itraconazole twice